Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Abbas

Showing results (791-800 of 827) with videos related to

Pageof 83
Sort By:
Leukemia|July 6, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase IIHannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, et al.
Genome Medicine|September 29, 2018
T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiencyErik L Clarke, A Jesse Connell, Emmanuelle Six, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Hemasphere|February 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapiesJayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Pageof 83

Showing results (791-800 of 827) with videos related to

Sort By:
Pageof 83
Leukemia|July 6, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase IIHannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, et al.
Genome Medicine|September 29, 2018
T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiencyErik L Clarke, A Jesse Connell, Emmanuelle Six, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Hemasphere|February 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapiesJayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Journal of Hematology & Oncology|November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemiasJayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
Pageof 83